When compared to Vorsetuzumab + KWAR23 treatment, the CD70/SIRPα bispecific antibody demonstrated an enhanced in-vitro phagocytosis of target tumor cells, but there was no apparent difference in in vivo efficacy observed (76). This evidence concerns the gene SIRPA and neoplasm.